Last reviewed · How we verify

Amvuttra — Competitive Intelligence Brief

Amvuttra (VUTRISIRAN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small Interfering RNA. Area: Neuroscience.

marketed Small Interfering RNA transthyretin (TTR) mRNA Neuroscience Oligonucleotide Live · refreshed every 30 min

Target snapshot

Amvuttra (VUTRISIRAN) — Alnylam Pharmaceuticals. Amvuttra works by silencing the production of abnormal TTR protein through RNA interference.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amvuttra TARGET VUTRISIRAN Alnylam Pharmaceuticals marketed Small Interfering RNA transthyretin (TTR) mRNA 2022-01-01
Onpattro PATISIRAN Alnylam Pharmaceuticals marketed Small Interfering RNA transthyretin (TTR) mRNA 2018-01-01
Onpattro PATISIRAN SODIUM Alnylam Pharmaceuticals marketed Small Interfering RNA transthyretin (TTR) mRNA 2018-01-01
SYL1001 ophthalmic solution SYL1001 ophthalmic solution Sylentis, S.A. phase 3 siRNA (small interfering RNA) TGF-β2 (transforming growth factor-beta 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Small Interfering RNA class)

  1. Alnylam Pharmaceuticals · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amvuttra — Competitive Intelligence Brief. https://druglandscape.com/ci/vutrisiran. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: